ADMP Adamis Pharmaceuticals Corporation

2.81
-0.08  -3%
Previous Close 2.89
Open 2.85
Price To Book 2.3
Market Cap 132888716
Shares 47,291,358
Volume 441,181
Short Ratio
Av. Daily Volume 393,817

SEC filingsSee all SEC filings

  1. 8-K - Current report 181223640
  2. 8-K - Current report 181184347
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173287
  4. 8-K - Current report 181092599
  5. 8-K - Current report 181056737

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 planned for December 2018.
APC-1000
Asthma/COPD
FDA Approval announced September 27, 2018.
Symjepi - low dose
Anaphylaxis
NDA filing due YE 2018.
APC-6000
Opioid overdose
NDA filing due 4Q 2018.
APC-8000 (sublingual tadalafil)

Latest News

  1. Novartis to launch Adamis' EpiPen rival in U.S. next year
  2. Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
  3. Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
  4. Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
  5. Adamis: 3Q Earnings Snapshot
  6. Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
  7. Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  8. Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Moving into 2018
  9. Could Adamis Pharmaceuticals Corporation’s (NASDAQ:ADMP) Investor Composition Impacts Your Returns?
  10. Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
  11. Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
  12. Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage
  13. Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
  14. Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
  15. Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
  16. Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
  17. Today’s Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals
  18. FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

SEC Filings

  1. 8-K - Current report 181223640
  2. 8-K - Current report 181184347
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173287
  4. 8-K - Current report 181092599
  5. 8-K - Current report 181056737
  6. 8-K - Current report 181009020
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005409
  8. 424B5 - Prospectus [Rule 424(b)(5)] 18990175
  9. 8-K - Current report 18986863
  10. 424B5 - Prospectus [Rule 424(b)(5)] 18984951